27

1

Logo

InterAx Biotech SA

Company | Switzerland

Primary tabs

About your organization

InterAx Biotech AG is a research-based Swiss company, spin-off from the ETH Zürich and the Paul Scherrer Institute (PSI). Our core expertise resides in the combination of cell-based real-time assays, including IP-protected biosensors, and proprietary big data analysis methods for the selection of the best drug molecules. InterAx has secured a seed-investment from Boston-based Biotech investors and has recently achieved an important milestone that triggered an additional cash inflow.

InterAx has established a novel GPCR lead discovery platform that efficiently delivers lead compounds that are hallmarked by confined cellular signaling profiles. This results in molecules with high efficacy and reduced adverse events. Our GPCR platform is unrestricted to a GPCR target, indication or type of compound, e.g. biologics or small molecules.

The InterAx discovery platform currently consists of three core assets: Virtual screening, state-of-the-art signaling assays including IP-protected protein-based biosensors for drug-induced signaling analysis, and systems biology for identification of most informative drug screening assays and prediction of in vivo effects. This unique combination ensures a highly efficient process for the identification of novel GPCR lead compounds. The lean design of the platform allows to conduct in-house projects in an early R&D stage towards IP-protection of novel compounds. 

InterAx Biotech and GPCR Therapeutics collaborate for the identification of compounds with superior biological properties targeting GPCR heteromers

Scope of the partnership
Industrial

InterAx Biotech and Boehringer Ingelheim collaborate for enabling the in-depth characterization of drug candidates

Scope of the partnership
Industrial

InterAx Biotech and Lundbeck A/S entered an agreement to enable the in-depth characterization of drug candidates

Scope of the partnership
Industrial

InterAx Biotech and Vrije Universiteit Amsterdam enter a collaboration to unlock novel chemical space for chemokine therapeutics

Scope of the partnership
Technological

Network (0)

There are no organizations in the network.

Recent activity

You are not connected

A certain number of contents are hidden from you and you do not benefit from the linking functionalities.

Log in or register to access to the entire contents and functionnalities. Subscription is quick and free.